master's thesis
KARCINOMI PLUĆA U MLADIH I NEPUŠAČA

Anđela Nadinić (2015)
Sveučilište u Rijeci
Medicinski fakultet
Katedra za onkologiju i radioterapiju
Metadata
TitleKARCINOMI PLUĆA U MLADIH I NEPUŠAČA
AuthorAnđela Nadinić
Mentor(s)Marija Petković (thesis advisor)
Abstract
Karcinom pluća u mlađoj životnoj dobi dominantno pogađa žene, nepušače i azijski etnicitet. Histološki prevladava adenokarcinom. Prilikom postavljanja dijagnoze 75% pacijenata već je u uznapredovaloj fazi bolesti. U usporedbi sa starijim pacijentima, bol je značajno češća u mlađoj populaciji što se može korelirati s visokom incidencijom zahvaćanja medijastinuma, pleure, prsnog koša i uznapredovalog stadija bolesti. Smatra se kako bi ulogu u nastanku adenokarcinoma pluća u mlađoj dobnoj skupini mogla imati visoka razina amplifikacije u dugom kraku kromosoma 20, postojanje ALK i EGFR mutacija. Postotak ALK pozitivnih NSCLC je 5 do 10% svih adenokarcinoma pluća, dok stopa EGFR mutacija nije drugačija u usporedbi sa starijim pacijentima. Sve važniju ulogu ima dijagnostičko molekularno testiranje kojim se utvrđuje status ALK i EGFR mutacija i tako omogućuje ciljana terapija koja će imati željeni učinak i pridonijeti poboljšanju dijagnoze. ALK i EGFR mutacije su usko povezane s boljim odgovorom na specifične kemoterapijske lijekove kao što su EGFR-TKI i ALK inhibitor. Unatoč napretku liječenja stopa petogodišnjeg preživljenja je 9-20 %.
Keywordsyoung non-smokers adenocarcinoma ALK mutation tyrosine kinase- inhibitors
GranterSveučilište u Rijeci
Medicinski fakultet
Lower level organizational unitsKatedra za onkologiju i radioterapiju
PlaceRijeka
StateCroatia
Scientific field, discipline, subdisciplineBIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Study programme typeuniversity
Study levelintegrated undergraduate and graduate
Study programmeMedicine
Academic title abbreviationdr. med.
Genremaster's thesis
Language Croatian
Defense date2015
Parallel abstract (English)
Lung cancer at younger age predominantly affects women, non-smoking and Asian ethnicity. Adenocarcinoma is the most common histological type. At the time of diagnosis 75% of the patients are already at an advanced stage of disease. Compared with older patients the pain is significantly more common in the younger population, and it can be correlated with a high incidence of grasping the mediastinum, pleura, chest and advanced stage of the disease. High levels of amplification in the long arm of chromosome 20, the existance of ALK and EGFR mutations are considered to be involved in the causation of lung adenocarcinom in young age groups. The percentage of ALK positive NSCLC is 5 to 10% of all lung adenocarcinoma, while EGFR mutation rate is not different in comparison with older patients. Increasingly important role has diagnostic molecular test that determines the status of ALK and EGFR mutations and thus enables targeted therapy that will have desired effect and contribute to improved diagnosis. ALK and EGFR mutations are correlated with better response to specific chemotherapeutic drugs such as EGFR-TKI and ALK inibitor. Despite the progress of treatment the five-year survival rate is 9-20%.
Parallel keywords (Croatian)mladi nepušači adenokarcinom ALK mutacija inhibitori tirozin-kinaze
Resource typetext
Access conditionAccess restricted to students and staff of home institution
Terms of usehttp://rightsstatements.org/vocab/InC/1.0/
URN:NBNhttps://urn.nsk.hr/urn:nbn:hr:184:576027
CommitterBosa Licul